A Study to Compare the Effect of Anti-VEGF Injection Combined with Dorzolamide - Timolol Eye Drops in Patients with Diabetic Macular Swelling

THE EFFECT OF COMBINATION THERAPY WITH INTRAVITREAL ANTI- VEGF AND TOPICAL DORZOLAMIDE TIMOLOL EYE DROPS ON DIABETIC MACULAR OEDEMA IN COMPARISON TO STANDALONE INTRAVITREAL ANTI-VEGF - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2025/09/094346

Enrollment

Registered

2025-09-08

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H350- Background retinopathy and retinalvascular changes

Interventions

Intervention1: dozolamide 2% timolol 0.5% eye drops combination along with avastin/anti vegf injection: dose : single drop, two times a day BD topically total duration : 4 months Control Interventio

Eligibility

Inclusion criteria

Inclusion criteria: Age more than 40yrs Patients with centre involving diabetic macular edema with central foveal thickness of more than 300 microns

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
To compare the anatomical and functional outcome with intravitreal bevacizumab(IVB) and topical timolol-dorzalamide versus intravitreal bevacizumab alone in terms of central foveal thicknessTimepoint: Baseline - 1st Visit After 4 weeks - 1st Follow Up After 8 weeks - 2nd Follow Up After 12 weeks - 3rd Follow Up	—

Secondary

Measure	Time frame
To check the variation in IOP of the patientTimepoint: Baseline - 1st Visit After 4 weeks - 1st Follow Up After 8 weeks - 2nd Follow Up After 12 weeks - 3rd Follow Up	—

Countries

India

Contacts

Public ContactNeel Nathmal Kavediya

Madras Medical College, Chennai

drhema0608@gmail.com6381914697

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026